MG
CRL icon

Mather Group’s Charles River Laboratories CRL Stock Holding History

Mather Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7K Buy
78
+27
+53% +$4.81K ﹤0.01% 1358
2026
Q1 		$8.8K Buy
+51
New +$9.46K ﹤0.01% 1477
2025
Q4 		– Sell
-124
Closed -$19.4K – 857
2025
Q3 		$19.4K Buy
+124
New +$19.7K ﹤0.01% 1127
2025
Q2 		– Sell
-667
Closed -$100K – 845
2025
Q1 		$100K Buy
667
+309
+86% +$51.8K ﹤0.01% 749
2024
Q4 		$66.1K Sell
358
-91
-20% -$17.5K ﹤0.01% 821
2024
Q3 		$88.4K Buy
449
+92
+26% +$19.1K ﹤0.01% 761
2024
Q2 		$96.7K Sell
357
-14
-4% -$3.17K ﹤0.01% 821
2024
Q1 		$87.7K Buy
+371
New +$88.6K ﹤0.01% 742

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Mather Group's CRL Position: Q2 2026 in Review

Mather Group increased its Charles River Laboratories (CRL) stake by 53% in Q2 2026, buying an estimated $4.81K and bringing the position to 78 shares worth $17.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1358.

Mather Group first reported a position in CRL in Q1 2024 and has held it in 8 quarters since. The position peaked at $100K in Q1 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Mather Group held 78 shares of Charles River Laboratories worth $17.7K as of Q2 2026.
  • Mather Group bought 27 Charles River Laboratories shares in Q2 2026, an estimated $4.81K.
  • Charles River Laboratories made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1358 holding.
  • Mather Group first reported a position in Charles River Laboratories in Q1 2024 and has held it in 8 quarters since.
  • Mather Group's Charles River Laboratories position peaked at $100K in Q1 2025.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.